R&D Trends

Report examines brand committees

Thursday, August 27, 2015

Life sciences organizations typically implement cross-functional brand commercialization committees to drive product development and maximize commercial success, according to a new study by pharmaceutical intelligence firm Cutting Edge Information. Those groups often are tasked with making key brand strategy decisions and with coordinating a broad range of brand activities throughout the product lifecycle.

[Read More]

Enumeral, UMass Medical ink agreement

Thursday, August 27, 2015

Enumeral Biomedical Holdings has entered into a research study agreement with University of Massachusetts Medical School, which includes the institution’s clinical partner, UMass Memorial HealthCare. UMass Medical will provide Enumeral with tissue samples and blood samples from subjects with melanoma who are being treated with Ipilimumab (Yervoy). Enumeral will fund the tissue collection activities, and Enumeral will have access to the samples for research-only use in in-vitro studies.

[Read More]

Agilent, Weill Cornell collaborate on ALS

Thursday, August 27, 2015

Agilent Technologies is collaborating with Dr. Steven Gross, a faculty member in the department of pharmacology at Weill Cornell Medical College in New York, to advance research in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Agilent will provide the latest mass spectrometry technology to support his research, working toward an understanding of how the most common form of the disease develops in the body.

[Read More]

Burning Rock, Illumina collaborate

Wednesday, August 26, 2015

Burning Rock, a Guangzhou, China-based diagnostics company, has entered into an agreement to develop advanced clinical applications for molecular diagnostics in oncology based on Illumina’s next-generation sequencing (NGS) technology. The collaboration highlights the  importance of genomics to improve healthcare in China.

[Read More]

Ocata receives lupus nephritis grant

Wednesday, August 26, 2015

Ocata Therapeutics, a Marlborough, Mass.-based clinical stage biotechnology company, has been awarded a Small Business Innovation Research (SBIR) phase I grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to fund further preclinical development of Ocata’s proprietary Hemangio-derived Mesenchymal Cell (HMC) product for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN).

[Read More]

Personalized medicine development tied to showing value of companion diagnostics

Monday, August 24, 2015

With interest in personalized medicines growing, drug and diagnostics companies are investing in the development of companion diagnostics that can show that their use in conjunction with personalized therapeutics will lead to positive health outcomes, according to R&D leaders participating in a roundtable recently hosted by the Tufts Center for the Study of Drug Development (CSDD).

[Read More]